Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

What is the chief complaint of patients hospitalized with a first myocardial infarction?

21 Sep 2020

Chest pain appears to be the principal complaint of patients hospitalized with a first myocardial infarction (MI), particularly among those in the youngest age group, a study has found.

The investigators sought to describe age differences in patients’ chief complaint associated with a first MI and how the “typicality” of acute symptoms related to the extent of prehospital delay. To do this, they reviewed the medical records of 2,586 residents of central Massachusetts, hospitalized at 11 greater Worcester medical centres with a first MI, on a biennial basis between 2001 and 2011.

Of the patients (mean age, 39.6 percent; 39.6 percent women), 40.2 percent were diagnosed with ST-elevation MI (STEMI) and 72.0 percent presented with typical symptoms of MI, namely acute chest pain or pressure. They were further categorized into five age strata: <55 years (23 percent), 55-64 years (20 percent), 65-74 years (19 percent), 75-84 years (22 percent), and ≥85 years (16 percent).

Atypical symptoms of MI were least observed in patients aged <55 years at 11 percent, increasing to 17 percent, 28 percent, 40 percent, and 51 percent across the respective age groups. At the time of hospitalization, chest pain turned out to be the most frequent chief complaint. However, the number of patients reporting this symptom fell from the youngest (83 percent) to the oldest groups (45 percent).

Furthermore, a slightly elevated risk of prehospital delay across the different age groups (higher in the oldest old) was observed in those who presented with atypical, rather than typical, symptoms of MI.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 6 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.